NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $5.69 -0.32 (-5.32%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.51▼$6.0450-Day Range$3.59▼$6.9752-Week Range$2.44▼$8.84Volume116,612 shsAverage Volume191,484 shsMarket Capitalization$287.41 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.7% Upside$13.75 Price TargetShort InterestBearish6.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 2 Articles This WeekInsider TradingSelling Shares$6,166 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector624th out of 910 stocksBiological Products, Except Diagnostic Industry99th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.52% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 0.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 2.6 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GLUE on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,166.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.89) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesSeptember 5 at 4:01 AM | americanbankingnews.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 3.3% August 24, 2024 | finance.yahoo.comCompanies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In GrowthSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 20, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 19, 2024 | globenewswire.comMonte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)August 9, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)August 8, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 8, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJuly 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJune 27, 2024 | globenewswire.comMonte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160June 14, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid ArthritisMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Leadership Team PromotionsMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)May 21, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$17.00 Low Stock Price Target$11.00 Potential Upside/Downside+141.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax Margin-2,256.14% Return on Equity-70.40% Return on Assets-44.71% Debt Debt-to-Equity RatioN/A Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual Sales$5.76 million Price / Sales49.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.55Miscellaneous Outstanding Shares50,512,000Free Float47,229,000Market Cap$287.41 million OptionableOptionable Beta1.44 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsC4 TherapeuticsNASDAQ:CCCCSeres TherapeuticsNASDAQ:MCRBKinnate BiopharmaNASDAQ:KNTEInvivydNASDAQ:IVVDKronos BioNASDAQ:KRONView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 132,614 shares on 8/9/2024Ownership: 0.504%Dimensional Fund Advisors LPBought 81,083 shares on 8/9/2024Ownership: 0.304%American Century Companies Inc.Bought 15,562 shares on 8/8/2024Ownership: 0.098%Meeder Asset Management Inc.Bought 10,050 shares on 8/8/2024Ownership: 0.020%Acadian Asset Management LLCBought 43,009 shares on 8/6/2024Ownership: 0.195%View All Insider TransactionsView All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, GLUE shares have increased by 0.7% and is now trading at $5.69. View the best growth stocks for 2024 here. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. The firm had revenue of $4.70 million for the quarter, compared to analysts' expectations of $3.20 million. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Top institutional investors of Monte Rosa Therapeutics include Renaissance Technologies LLC (0.50%), Dimensional Fund Advisors LP (0.30%), Bank of New York Mellon Corp (0.22%) and Acadian Asset Management LLC (0.20%). View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
